Antisense oligonucleotides have proven effective at preventing protein synthesis as a result of their on-target specificity. Recent data from several clinical trials including a phase I trial targeting Lp(a), published in The Lancet, highlight the therapeutic potential of antisense oligonucleotides in regulating plasma lipid levels.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tsimikas, S. et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet http://dx.doi.org/10.1016/S0140-6736(15)61252-1.
Gaudet, D. et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N. Engl. J. Med. 373, 438–447 (2015).
Sabatine, M. S. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500–1509 (2015).
Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489–1499 (2015).
Koschinsky, M. L. & Boffa, M. B. Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum. Endocrinol. Metab. Clin. North. Am. 43, 949–962 (2014).
Clarke, R. et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518–2528 (2009).
Kamstrup, P. R., Tybjaerg-Hansen, A. & Nordestgaard, B. G. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J. Am. Coll. Cardiol. 63, 470–477 (2014).
Alonso, R. et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J. Am. Coll. Cardiol. 63, 1982–1989 (2014).
Thomas, G. S. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 62, 2178–2184 (2013).
Romagnuolo, R. et al. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J. Biol. Chem. 290, 11649–11662 (2015).
Acknowledgements
R.A.H. is supported by grants from the Canadian Institutes of Health Research (Foundation Program), the Heart and Stroke Foundation (Project G-15-0009214), and Genome Canada (through Genome Quebec). S.M.K.F. is supported by the Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarship.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.A.H. consults for Aegerion, Amgen, Boston Heart Diagnostics, ISIS, Lilly, Merck, Pfizer, Sanofi and Valeant Pharmaceuticals. S.M.K.F. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Farhan, S., Hegele, R. Antisenses working overtime in lipids. Nat Rev Endocrinol 11, 574–576 (2015). https://doi.org/10.1038/nrendo.2015.146
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2015.146